Mersana Therapeutics(US:MRSN)2023-03-13 00:24UpRi (Upifitamab Rilsodotin) Development - Mersana expects top-line data from the registrational UPLIFT trial in platinum-resistant ovarian cancer in mid-2023, with a potential BLA submission targeted around the end of 2023[3],[19] - The ongoing UP-NEXT Phase 3 trial in recurrent platinum-sensitive ovarian cancer has the potential to support global registrations[7] - Mersana initiated a Phase 3 UP-NEXT trial and is conducting the UPGRADE-A Phase 1 combo trial in platinum-sensitive ovarian cancer[15],[7] - In a prior phase 1b clinical trial, 67% of patients with NaPi2b-positive ovarian cancer had a target lesion reduction from baseline[76] - In the same trial, the ORR in the NaPi2b-positive population in dose group 36 was 39%[76] - Approximately 58.9% NaPi2b positivity (TPS≥75) rate in 397 ovarian cancer tumor samples[71] Pipeline and Platform Innovation - Mersana's Dolasynthen platform is utilized for XMT-1660, and Janssen collaboration[13] - Mersana's Immunosynthen platform is utilized for XMT-2056 (GSK option), XMT-2068, XMT-2175, Merck KGaA, Darmstadt, Germany collaboration[13] - XMT-2056 targets a novel HER2 epitope and has received FDA Orphan Drug designation for gastric cancer[7],[40] - XMT-1660 has been granted Fast Track designation in the United States for advanced or metastatic triple negative breast cancer (TNBC)[12],[107] Business Development and Financials - Mersana secured collaborations in 2022, including $170 million in upfront payments and over $3 billion in potential milestones[3] - Collaborations include Janssen ($40 million upfront, >$1 billion in potential milestones + royalties), Merck KGaA, Darmstadt, Germany ($30 million upfront, up to $800 million in potential milestones + royalties), and GSK ($100 million upfront, up to $1.3 billion in potential payments + royalties/profit share)[11],[12],[15],[68] - Capital resources are expected to support operating plan commitments into the second half of 2024[12]